Cadherin 6 drives epithelial-mesenchymal transition and oxaliplatin resistance in gastric cancer via transforming growth factor-β/Smad signaling axis

Figure 3 Cadherin 6 overexpression promotes gastric cancer growth and mediates oxaliplatin resistance in vivo. A: Changes in mouse body weight over time. Body weights of mice in the control, cadherin 6 (CDH6)-overexpression (OE-CDH6), oxaliplatin, and oxaliplatin + OE-CDH6 groups were monitored during the experiment; B: Representative images of mice in each group; C: Gross appearance of tumors from each group; D: Tumor volume analysis. Tumor volume was significantly greater in the OE-CDH6 group than in the control group, and in the oxaliplatin + OE-CDH6 group compared to the oxaliplatin group, indicating that CDH6 overexpression drives gastric cancer proliferation and confers resistance to oxaliplatin. Control group vs OE-CDH6 group (P = 0.0017); oxaliplatin group vs oxaliplatin + OE-CDH6 group (P = 0.027). ^aP < 0.05, ^bP < 0.01, and ^cP < 0.001. OE-CDH6: Cadherin 6-overexpression.